Zacks Investment Research upgraded shares of Sartorius (OTCMKTS:SARTF) from a hold rating to a buy rating in a research report sent to investors on Wednesday, Zacks.com reports. Zacks Investment Research currently has $192.00 price objective on the stock.
According to Zacks, “Sartorius AG is a pharmaceutical and laboratory equipment supplier. The company manufactures equipment for biomolecular and microbial separations, cell culture, concentration, fermentation and purification. Sartorius AG is headquartered in Goettingen, Germany. “
SARTF has been the subject of several other research reports. DZ Bank reissued a sell rating on shares of Sartorius in a research report on Tuesday, April 2nd. ValuEngine raised shares of Sartorius from a hold rating to a buy rating in a research report on Friday, March 15th.
Sartorius (OTCMKTS:SARTF) last released its earnings results on Thursday, April 18th. The company reported $0.81 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.65 by $0.16. Sartorius had a net margin of 10.28% and a return on equity of 18.90%. The business had revenue of $494.79 million during the quarter, compared to analysts’ expectations of $439.53 million. As a group, sell-side analysts anticipate that Sartorius will post 3.45 earnings per share for the current year.
There is no company description available for Sartorius AG.
Read More: Commodities
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sartorius Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sartorius and related companies with MarketBeat.com's FREE daily email newsletter.